The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.
 
David M. O'Malley
Consulting or Advisory Role - Abbvie; Agenus; Ambry Genetics; AstraZeneca; Clovis Oncology; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; Iovance Biotherapeutics; Janssen Oncology; Leap Therapeutics; Marker Therapeutics; Myriad Genetics; Novartis; Novocure; OncoQuest; Regeneron; Rubius Therapeutics; Rubius Therapeutics; Seagen; Sorrento Therapeutics; Tarveda Therapeutics; Tesaro; Translational Genomics Research Institute
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Agenus (Inst); Ajinomoto (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); EMD Serono (Inst); Ergomed (Inst); Genentech/Roche (Inst); Genmab (Inst); Immunogen (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Leap Therapeutics (Inst); Merck (Inst); Mersana (Inst); PharmaMar (Inst); Regeneron (Inst); Seagen (Inst); Tesaro (Inst); TRACON Pharma (Inst)
 
Ana Oaknin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Deciphera; Genmab; GlaxoSmithKline; Immunogen; Mersana; PharmaMar; Roche; Tesaro
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Clovis Oncology (Inst); Eisai (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche
 
Ursula A. Matulonis
Honoraria - Advaxis
Consulting or Advisory Role - Merck; NextCure; Novartis
Research Funding - Fujifilm; Immunogen; Leap Therapeutics; Merck; Mersana; Novartis; SQZ Biotech; Syndax; Tesaro
Travel, Accommodations, Expenses - AstraZeneca
 
Gina Mantia-Smaldone
Honoraria - Tesaro
Consulting or Advisory Role - Tesaro
 
Peter C Lim
No Relationships to Disclose
 
Cesar Martin Castro
Consulting or Advisory Role - Advanced Medical; InfiniteMD; Qiagen
Research Funding - Clovis Oncology; Merck Sharp & Dohme; Millenium Pharamceuticals
Patents, Royalties, Other Intellectual Property - Co-inventor: Holographic diagnostic profiling; Co-inventor: Nanoplasmonic exosome profiling
 
Diane M. Provencher
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Research Funding - Abbvie; AstraZeneca
 
Sanaz Memarzadeh
No Relationships to Disclose
 
Patrick A. Zweidler-McKay
Employment - Immunogen
Stock and Other Ownership Interests - Immunogen
Patents, Royalties, Other Intellectual Property - Patent applications submitted, no royalties
 
Jiuzhou Wang
Employment - ImmunoGen
Stock and Other Ownership Interests - ImmunoGen
Travel, Accommodations, Expenses - ImmunoGen
 
Brooke Esteves
Employment - ImmunoGen
Stock and Other Ownership Interests - ImmunoGen
Travel, Accommodations, Expenses - ImmunoGen
 
Kathleen N. Moore
Honoraria - Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - Abbvie; Aravive; AstraZeneca (Inst); Eisai; Genentech/Roche; Immunogen; Merck; Mersana (Inst); Myriad Genetics; Pfizer/EMD Serono; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
 
Lucy Gilbert
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck
Consulting or Advisory Role - GlaxoSmithKline; Merck
Research Funding - Alkermes (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Immunogen (Inst); IMV (Inst); Inovio Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck; Pfizer